177 related articles for article (PubMed ID: 28779995)
21. HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Pinheiro M; Drigo SA; Tonhosolo R; Andrade SCS; Marchi FA; Jurisica I; Kowalski LP; Achatz MI; Rogatto SR
Oncotarget; 2017 Jun; 8(25):40896-40905. PubMed ID: 28402931
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer.
Vriens MR; Suh I; Moses W; Kebebew E
Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717
[TBL] [Abstract][Full Text] [Related]
23. G534E Variant in HABP2 and Nonmedullary Thyroid Cancer.
Ruiz-Ferrer M; Fernández RM; Navarro E; Antiñolo G; Borrego S
Thyroid; 2016 Jul; 26(7):987-8. PubMed ID: 27245704
[No Abstract] [Full Text] [Related]
24. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
[TBL] [Abstract][Full Text] [Related]
25. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
Bauer AJ
Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
[TBL] [Abstract][Full Text] [Related]
26. [Clinical and biological features of familial nonmedullary thyroid carcinoma].
Gao J; Yu Y; Li X; Zhao J; Zhao C; Zhao J; Liu Y; Li Y; Gao M
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):202-6. PubMed ID: 24785281
[TBL] [Abstract][Full Text] [Related]
27. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
28. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
29. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
30. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
31. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and prognosis of familial nonmedullary thyroid carcinoma.
de Carlos Artajo J; Irigaray Echarri A; García Torres J; Pineda Arribas JJ; Ernaga Lorea A; Eguílaz Esparza N; Zubiría Gortázar JM; Anda Apiñániz E
Endocrinol Diabetes Nutr (Engl Ed); 2022 Apr; 69(4):262-270. PubMed ID: 35353680
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
34. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
[TBL] [Abstract][Full Text] [Related]
35. Familial nonmedullary thyroid cancer: a review of the genetics.
Khan A; Smellie J; Nutting C; Harrington K; Newbold K
Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
[TBL] [Abstract][Full Text] [Related]
36. Results of Screening in Familial Non-Medullary Thyroid Cancer.
Klubo-Gwiezdzinska J; Yang L; Merkel R; Patel D; Nilubol N; Merino MJ; Skarulis M; Sadowski SM; Kebebew E
Thyroid; 2017 Aug; 27(8):1017-1024. PubMed ID: 28657510
[TBL] [Abstract][Full Text] [Related]
37. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
38. Genetic predisposition to papillary thyroid cancer.
Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D
Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463
[TBL] [Abstract][Full Text] [Related]
39. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
[TBL] [Abstract][Full Text] [Related]
40. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
